Do analysts rate IBRX or MESO?

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 98.05%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts plainly believe ImmunityBio is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is IBRX or MESO more profitable?

Mesoblast has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Mesoblast N/A N/A N/A

Does the media favor IBRX or MESO?

In the previous week, ImmunityBio had 9 more articles in the media than Mesoblast. MarketBeat recorded 12 mentions for ImmunityBio and 3 mentions for Mesoblast. ImmunityBio's average media sentiment score of 0.57 beat Mesoblast's score of 0.00 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MESO or MIRM?

Mirum Pharmaceuticals has a consensus target price of $143.40, indicating a potential upside of 35.35%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Mirum Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.93

Does the media prefer MESO or MIRM?

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 3 mentions for Mesoblast. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Mesoblast's score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate COGT or MESO?

Cogent Biosciences presently has a consensus target price of $45.90, suggesting a potential upside of 17.90%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cogent Biosciences is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.85 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is COGT or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Mesoblast N/A N/A N/A

Does the media refer more to COGT or MESO?

In the previous week, Cogent Biosciences had 8 more articles in the media than Mesoblast. MarketBeat recorded 11 mentions for Cogent Biosciences and 3 mentions for Mesoblast. Cogent Biosciences' average media sentiment score of 1.53 beat Mesoblast's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer LNTH or MESO?

Lantheus presently has a consensus price target of $109.71, suggesting a potential upside of 10.11%. Given Lantheus' stronger consensus rating and higher possible upside, equities analysts plainly believe Lantheus is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings and valuation, LNTH or MESO?

Lantheus has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.21 $233.56M $4.15 24.01 Mesoblast $17.20M 107.00 -$102.14M -$0.28 N/A

Is LNTH or MESO more profitable?

Lantheus has a net margin of 18.05% compared to Mesoblast's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Mesoblast's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Mesoblast N/A N/A N/A

Does the media refer more to LNTH or MESO?

In the previous week, Lantheus had 11 more articles in the media than Mesoblast. MarketBeat recorded 14 mentions for Lantheus and 3 mentions for Mesoblast. Lantheus' average media sentiment score of 0.33 beat Mesoblast's score of 0.00 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CGON or MESO?

CG Oncology presently has a consensus target price of $81.73, suggesting a potential upside of 14.80%. Given CG Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe CG Oncology is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.71 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, CGON or MESO?

Mesoblast has higher revenue and earnings than CG Oncology. Mesoblast is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,554.20 -$160.99M -$2.33 N/A Mesoblast $17.20M 107.00 -$102.14M -$0.28 N/A

Is CGON or MESO more profitable?

Mesoblast's return on equity of 0.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Mesoblast N/A N/A N/A

Does the media favor CGON or MESO?

In the previous week, CG Oncology had 11 more articles in the media than Mesoblast. MarketBeat recorded 14 mentions for CG Oncology and 3 mentions for Mesoblast. CG Oncology's average media sentiment score of 0.93 beat Mesoblast's score of 0.00 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Mesoblast (MESO) Competitors

$14.17 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$14.10 -0.06 (-0.46%)

As of 07/31/2026 07:34 PM Eastern

Compare

MESO vs. IBRX, MIRM, COGT, LNTH, and CGON

Should you buy Mesoblast stock or one of its competitors? MarketBeat compares Mesoblast with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mesoblast include ImmunityBio (IBRX), Mirum Pharmaceuticals (MIRM), Cogent Biosciences (COGT), Lantheus (LNTH), and CG Oncology (CGON).

How does Mesoblast compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mesoblast has lower revenue, but higher earnings than ImmunityBio. Mesoblast is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	66.29	-$351.40M	-$0.85	N/A
Mesoblast	$17.20M	107.00	-$102.14M	-$0.28	N/A

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 98.05%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts plainly believe ImmunityBio is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Mesoblast has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Mesoblast	N/A	N/A	N/A

ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

In the previous week, ImmunityBio had 9 more articles in the media than Mesoblast. MarketBeat recorded 12 mentions for ImmunityBio and 3 mentions for Mesoblast. ImmunityBio's average media sentiment score of 0.57 beat Mesoblast's score of 0.00 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ImmunityBio beats Mesoblast on 9 of the 16 factors compared between the two stocks.

How does Mesoblast compare to Mirum Pharmaceuticals?

Mesoblast (NASDAQ:MESO) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 3 mentions for Mesoblast. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Mesoblast's score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	107.00	-$102.14M	-$0.28	N/A
Mirum Pharmaceuticals	$569.61M	11.34	-$23.36M	-$13.61	N/A

1.4% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mirum Pharmaceuticals has a consensus target price of $143.40, indicating a potential upside of 35.35%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mesoblast has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mesoblast's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Mesoblast has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

Summary

Mesoblast and Mirum Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Mesoblast compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, Cogent Biosciences had 8 more articles in the media than Mesoblast. MarketBeat recorded 11 mentions for Cogent Biosciences and 3 mentions for Mesoblast. Cogent Biosciences' average media sentiment score of 1.53 beat Mesoblast's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.4% of Mesoblast shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Comparatively, 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cogent Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Mesoblast's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Mesoblast	N/A	N/A	N/A

Mesoblast has higher revenue and earnings than Cogent Biosciences. Mesoblast is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Mesoblast	$17.20M	107.00	-$102.14M	-$0.28	N/A

Cogent Biosciences presently has a consensus target price of $45.90, suggesting a potential upside of 17.90%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cogent Biosciences is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Mesoblast beats Cogent Biosciences on 8 of the 15 factors compared between the two stocks.

How does Mesoblast compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lantheus presently has a consensus price target of $109.71, suggesting a potential upside of 10.11%. Given Lantheus' stronger consensus rating and higher possible upside, equities analysts plainly believe Lantheus is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Lantheus has a net margin of 18.05% compared to Mesoblast's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Mesoblast	N/A	N/A	N/A

Lantheus has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.21	$233.56M	$4.15	24.01
Mesoblast	$17.20M	107.00	-$102.14M	-$0.28	N/A

Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

In the previous week, Lantheus had 11 more articles in the media than Mesoblast. MarketBeat recorded 14 mentions for Lantheus and 3 mentions for Mesoblast. Lantheus' average media sentiment score of 0.33 beat Mesoblast's score of 0.00 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lantheus beats Mesoblast on 13 of the 17 factors compared between the two stocks.

How does Mesoblast compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Mesoblast has higher revenue and earnings than CG Oncology. Mesoblast is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,554.20	-$160.99M	-$2.33	N/A
Mesoblast	$17.20M	107.00	-$102.14M	-$0.28	N/A

CG Oncology has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market.

CG Oncology presently has a consensus target price of $81.73, suggesting a potential upside of 14.80%. Given CG Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe CG Oncology is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Mesoblast's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Mesoblast	N/A	N/A	N/A

In the previous week, CG Oncology had 11 more articles in the media than Mesoblast. MarketBeat recorded 14 mentions for CG Oncology and 3 mentions for Mesoblast. CG Oncology's average media sentiment score of 0.93 beat Mesoblast's score of 0.00 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CG Oncology and Mesoblast tied by winning 8 of the 16 factors compared between the two stocks.

Get Mesoblast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MESO vs. The Competition

Export

Metric	Mesoblast	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.84B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-50.61	7.38	282.30	24.66
Price / Sales	107.00	1,182.44	561.34	76.65
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	3.03	16.96	10.98	6.07
Net Income	-$102.14M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-2.68%	-1.76%	-0.60%	-0.44%
1 Month Performance	-1.46%	-8.38%	-5.20%	-4.81%
1 Year Performance	-6.59%	48.40%	62.01%	18.61%

Mesoblast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MESO Mesoblast	0.3309 of 5 stars	$14.17 flat	N/A	-6.6%	$1.84B	$17.20M	N/A	80	Gap Up
IBRX ImmunityBio	2.5412 of 5 stars	$6.68 -4.4%	$14.20 +112.5%	+202.5%	$7.00B	$140.98M	N/A	590	Upcoming Earnings Gap Up
MIRM Mirum Pharmaceuticals	3.3361 of 5 stars	$112.07 -1.9%	$143.40 +28.0%	+103.7%	$6.84B	$569.61M	N/A	140	Positive News Upcoming Earnings
COGT Cogent Biosciences	2.1996 of 5 stars	$39.26 -2.9%	$45.90 +16.9%	+241.5%	$6.71B	N/A	N/A	80	Positive News Upcoming Earnings Gap Up
LNTH Lantheus	3.1989 of 5 stars	$102.28 -5.3%	$110.43 +8.0%	+41.2%	$6.66B	$1.54B	24.65	1,193	Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MESO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesoblast (MESO) Competitors

MESO vs. IBRX, MIRM, COGT, LNTH, and CGON

How does Mesoblast compare to ImmunityBio?

Summary

How does Mesoblast compare to Mirum Pharmaceuticals?

Summary

How does Mesoblast compare to Cogent Biosciences?

Summary

How does Mesoblast compare to Lantheus?

Summary

How does Mesoblast compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesoblast (MESO) Competitors

MESO vs. IBRX, MIRM, COGT, LNTH, and CGON

How does Mesoblast compare to ImmunityBio?

Do insiders & institutionals have more ownership in IBRX or MESO?

Which has preferable earnings & valuation, IBRX or MESO?

Do analysts rate IBRX or MESO?

Is IBRX or MESO more profitable?

Which has more risk and volatility, IBRX or MESO?

Does the media favor IBRX or MESO?

Summary

How does Mesoblast compare to Mirum Pharmaceuticals?

Does the media prefer MESO or MIRM?

Which has better earnings and valuation, MESO or MIRM?

Do institutionals & insiders believe in MESO or MIRM?

Do analysts rate MESO or MIRM?

Is MESO or MIRM more profitable?

Which has more risk and volatility, MESO or MIRM?

Summary

How does Mesoblast compare to Cogent Biosciences?

Does the media refer more to COGT or MESO?

Do insiders and institutionals believe in COGT or MESO?

Which has more volatility & risk, COGT or MESO?

Is COGT or MESO more profitable?

Which has better valuation and earnings, COGT or MESO?

Do analysts rate COGT or MESO?

Summary

How does Mesoblast compare to Lantheus?

Do insiders & institutionals hold more shares of LNTH or MESO?

Do analysts prefer LNTH or MESO?

Is LNTH or MESO more profitable?

Which has better earnings and valuation, LNTH or MESO?

Which has more risk & volatility, LNTH or MESO?

Does the media refer more to LNTH or MESO?

Summary

How does Mesoblast compare to CG Oncology?

Which has preferable earnings and valuation, CGON or MESO?

Which has more volatility & risk, CGON or MESO?

Do analysts recommend CGON or MESO?

Is CGON or MESO more profitable?

Does the media favor CGON or MESO?

Do institutionals & insiders hold more shares of CGON or MESO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools